Skip navigation
Browsing by Author Cohen, B.
Showing results 1 to 1 of 1
| Preview | Issue Date | Title / Name | Author(s) |
| Nov-2024 | Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study | Cohen, B.; Rapoport, B.; Chan, S. w.; Ruff, P.; Arance, A.; Eizmendi, K. M.; Houghton, B.; Brown, M. P.; Zielinski, R. M.; Couselo, E. M.; Lyle, M.; Anderson, J. R.; Jain, L.; de Alwis, D.; Lala, M.; Akala, O.; Chartash, E.; Jacobs, C.; Houghton, Baerin | |
